Basis: (FMP quote price / unrounded diluted TTM EPS) / explicitly dated EPS growth percent. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-09-15T15:15:27.310Z.
Calculation as of: 2026-09-15T15:15:27.310Z.
Quote observation: 2026-09-15T15:15:23.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 26c01ddac3b876b961f96101794b65021049dda1f01dad89527483030718ef9a
PEG RATIO
N/A
Abbott Laboratories
Market Cap
$176.12B
PEG Ratio
N/A
| NAME | MARKET CAP | PEG RATIO |
|---|---|---|
| Abbott Laboratories (ABT) | $176.12B | N/A |
| Gilead Sciences, Inc. (GILD)vs › | $179.39B | N/A |
| Novo Nordisk A/S (NVO)vs › | $189.35B | N/A |
| Pfizer Inc. (PFE)vs › | $156.71B | N/A |
| Amgen Inc. (AMGN)vs › | $203.11B | N/A |
| Danaher Corporation (DHR)vs › | $145.25B | N/A |
| Intuitive Surgical, Inc. (ISRG)vs › | $131.30B | N/A |
| Vertex Pharmaceuticals Incorporated (VRTX)vs › | $129.91B | N/A |
| Bristol-Myers Squibb Company (BMY)vs › | $130.01B | N/A |
| CVS Health Corp. (CVS)vs › | $120.19B | N/A |
PEG Ratio
N/A
P/E Ratio
32.7
PEG Ratio = PE Ratio / Earnings Growth Rate
The PEG ratio adjusts the PE ratio for expected earnings growth. A PEG near 1 is often considered fairly valued relative to growth.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute